Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ASLAN PHARMACEUTICALS LIMITED

(ASLN)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 10/28 12:48:23 pm
1.615 USD   -3.29%
11:05aAsian ADRs Move Up in Thursday Trading
MT
10/27Asian ADRs Move Lower in Wednesday Trading
MT
10/26Asian ADRs Modestly Lower Tuesday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

09/27/2021 | 06:00am EDT

ASLAN Pharmaceuticals Limited announced positive topline data from its randomized, double-blind, placebo-controlled, 8-week, multiple-ascending-dose (MAD) Phase 1 study of ASLAN004 for the treatment of moderate-to-severe atopic dermatitis (AD). ASLAN004, a potential first-in-class monoclonal antibody that targets the IL-13 receptor, was shown to be well tolerated across all doses. Data from the study conclusively establishes proof of concept, and supports the potential of ASLAN004 as a differentiated, novel treatment for AD. ASLAN004 achieved a statistically significant improvement (p


ę S&P Capital IQ 2021
All news about ASLAN PHARMACEUTICALS LIMITED
11:05aAsian ADRs Move Up in Thursday Trading
MT
10/27Asian ADRs Move Lower in Wednesday Trading
MT
10/26Asian ADRs Modestly Lower Tuesday
MT
10/26ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corpora..
AQ
10/26ASLAN PHARMACEUTICALS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORA..
PU
10/22Asian ADRs Flat in Friday Trading
MT
10/22ASLAN PHARMACEUTICALS : Collaborates With Skin Disease Expert on Study of Potential Atopic..
MT
10/21ASLAN PHARMACEUTICALS : Aslan003
PU
10/21ASLAN PHARMACEUTICALS : Aslan004
PU
10/20Asian ADRs Nudge Higher in Wednesday Trading
MT
More news
Analyst Recommendations on ASLAN PHARMACEUTICALS LIMITED
More recommendations
Financials
Sales 2021 - - -
Net income 2021 -848 M -30,5 M -30,5 M
Net Debt 2021 - - -
P/E ratio 2021 -3,17x
Yield 2021 -
Capitalization 3 228 M 116 M 116 M
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 18
Free-Float 41,2%
Chart ASLAN PHARMACEUTICALS LIMITED
Duration : Period :
ASLAN Pharmaceuticals Limited Technical Analysis Chart | ASLN | US04522R1014 | MarketScreener
Technical analysis trends ASLAN PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 1,67 $
Average target price 8,00 $
Spread / Average Target 379%
EPS Revisions
Managers and Directors
Carl Aslan Jason Morton Firth Chief Executive Officer & Director
Kiran Kumar Asarpota Chief Operating Officer & Head-Finance
Andrew James Howden Non-Executive Chairman
Kenneth Kobayashi Chief Medical Officer
Robert E. Hoffman Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ASLAN PHARMACEUTICALS LIMITED-8.74%116
GILEAD SCIENCES, INC.14.61%83 717
BIONTECH SE241.97%67 329
WUXI APPTEC CO., LTD.20.76%62 553
REGENERON PHARMACEUTICALS22.04%61 299
VERTEX PHARMACEUTICALS-23.44%46 941